HIV-1 RECOMBINANT GP160 VACCINE GIVEN IN ACCELERATED DOSE SCHEDULES

被引：0
|
作者：
DEPALMA, L
机构：
来源：
PEDIATRIC AIDS AND HIV INFECTION-FETUS TO ADOLESCENT | 1995年 / 6卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：97 / 98
页数：2
相关论文
共 50 条
  • [21] SYNTHESIS AND PROCESSING OF HIV-1 GP160 IN CELLS WITH DEFECTIVE HIV-1 GENOMES
    KALYANARAMAN, VS
    RODRIGUEZ, V
    GALLO, RC
    SARNGADHARAN, MG
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1991, 7 (02) : 197 - 197
  • [22] ENVELOPE-SPECIFIC ANTIBODIES IN THE SALIVA OF INDIVIDUALS VACCINATED WITH RECOMBINANT HIV-1 GP160
    VASUDEVACHARI, MB
    UFFELMAN, KW
    KOVACS, J
    YEH, CK
    LANE, HC
    SALZMAN, NP
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1992, 5 (08): : 817 - 821
  • [23] Immunological aspects of patients with HIV-1 disease following immunization with recombinant gp160 (VaxSyn)
    Guerra, E
    Ricci, G
    Carlesimo, M
    Varani, AR
    Pontesilli, O
    Scala, E
    Mezzaroma, I
    Pierdominici, M
    Pandolfi, F
    Antinori, A
    DeLuca, A
    Murri, R
    Ammassari, A
    Ortona, L
    Aiuti, F
    DEVELOPMENT AND APPLICATIONS OF VACCINES AND GENE THERAPY IN AIDS, 1996, 48 : 147 - 154
  • [24] SAFETY AND IMMUNOGENICITY OF LAMBDA-BACULOVIRUS DERIVED HIV-1 IIIB RECOMBINANT GP160 VACCINE (VAXSYN(R)) IN HUMANS
    KEEFER, M
    BELSHE, R
    CLEMENTS, M
    GRAHAM, B
    COREY, L
    BOLOGNESI, D
    STABLEIN, D
    FAST, P
    MONTEFIORI, D
    SMITH, G
    DOLIN, R
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1993, 9 : S113 - S113
  • [25] THE SAFETY AND IMMUNOGENICITY OF A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) RECOMBINANT GP160 CANDIDATE VACCINE IN HUMANS
    DOLIN, R
    GRAHAM, BS
    GREENBERG, SB
    TACKET, CO
    BELSHE, RB
    MIDTHUN, K
    CLEMENTS, ML
    GORSE, GJ
    HORGAN, BW
    ATMAR, RL
    KARZON, DT
    BONNEZ, W
    FERNIE, BF
    MONTEFIORI, DC
    STABLEIN, DM
    SMITH, GE
    KOFF, WC
    ANNALS OF INTERNAL MEDICINE, 1991, 114 (02) : 119 - 127
  • [26] PROTECTION OF CHIMPANZEES FROM INFECTION BY HIV-1 AFTER VACCINATION WITH RECOMBINANT GLYCOPROTEIN GP120 BUT NOT GP160
    BERMAN, PW
    GREGORY, TJ
    RIDDLE, L
    NAKAMURA, GR
    CHAMPE, MA
    PORTER, JP
    WURM, FM
    HERSHBERG, RD
    COBB, EK
    EICHBERG, JW
    NATURE, 1990, 345 (6276) : 622 - 625
  • [27] WHICH GP160 VACCINE
    MOORE, J
    LEWIS, GK
    ROBINSON, J
    NATURE, 1993, 361 (6412) : 503 - 503
  • [28] Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160
    Lee, D
    Graham, BS
    Chiu, YL
    Gilbert, PB
    McElrath, MJ
    Belshe, RB
    Buchbinder, SP
    Sheppard, HW
    Koblin, BA
    Mayer, KH
    Keefer, MC
    Mulligan, MJ
    Celum, CL
    JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (05): : 903 - 907
  • [29] Heparin enhances the furin cleavage of HIV-1 gp160 peptides
    Pasquato, A.
    Dettin, M.
    Basak, A.
    Gambaretto, R.
    Tonin, L.
    Seidah, N. G.
    Di Bello, C.
    FEBS LETTERS, 2007, 581 (30) : 5807 - 5813
  • [30] FURIN IS IMPORTANT BUT NOT ESSENTIAL FOR THE PROTEOLYTIC MATURATION OF GP160 OF HIV-1
    GU, ML
    RAPPAPORT, J
    LEPPLA, SH
    FEBS LETTERS, 1995, 365 (01) : 95 - 97
12345